Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cell therapy targets Hard-to-Treat bile duct cancers

NCT ID NCT07614061

First seen Jun 03, 2026 · Last updated Jun 14, 2026 · Updated 3 times

Summary

This early-stage study tests a new treatment called BTC-Ag-T for people with advanced bile duct or gallbladder cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check the safety of this approach and see if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Zhongshan Hospital, Fudan University

    RECRUITING

    Shanghai, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms Cholangiocarcinoma Gallbladder Neoplasms Klatskin Tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.